Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Rituximab in Waldenstrom's Macroglobulinemia
NCT00422799Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2006
- Primary completion
- Oct 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Aug 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00422799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422799.